Other talks in the #ClinicalTrials and #biomarkers Alzheimer's Association #Immunity23 included The National Institute on Aging (NIA) Keenan Walker Columbia University Devenand INmune Bio Inc. CJ Barnum David Gate Lynn vanOlst Brigham and Women's Hospital Caroline Wasen & Laijun Lai

“The z-Movi allows us to dissect the temporal nature of the synaptic formation between #NKcell and #tumorcell [...] giving us perfect tool to measure potency of batches of INKmune NK cells.” — Prof. Mark Lowdell, CSO, INmune Bio Inc.. Full case study:⬇️
bit.ly/3wJj778…

Cumulus Neuroscience is proud to work with INmune Bio Inc. on a ground-breaking study in #Alzheimers where XPro1595, a protein biologic with a novel MOA targeting pathological inflammation, will be assessed using #digitalbiomarkers in a real-world setting, in clinic & at home. #CNS

Our CFO David Moss has been featured in a recent CBS News article discussing the groundbreaking developments in #Alzheimers research and #healthcare economics. Read the full article to learn more about Alzheimer's research and healthcare economics: cbsn.ws/3OKgaxc

Hey INmune Bio Inc.(INmune Bio Inc.), thank you for following me

Hey INmune Bio Inc.! Welcome to my feed! Excited to have a cutting-edge biotech company like you on board. Looking forward to learning more about your innovative therapies for cancer and Alzheimer's disease. Let's connect and share some groundbreaking ideas!

September is World #Alzheimers Month. We're honored to work with INmune Bio Inc. on a Ph1 POC study of XPro1595, a protein biologic with a novel MOA targeting pathological inflammation using #digitalbiomarkers in a real-world setting, both in-clinic and at home

Day 2 Track 1 of Biomarkers 2023 will feature industry insights & sponsored presentations from Step Pharma Imperial College London, Wellcome, Merck, Cambridge Cognition, INmune Bio Inc., Bio-Techne, Quanterix & more! Register here: hubs.la/Q01zzYw80

#BiomarkersSeries23

September is World #Alzheimers Month. We're honored to work with INmune Bio Inc. on a Ph1 POC study of XPro1595, a protein biologic with a novel MOA targeting pathological inflammation using #digitalbiomarkers in a real-world setting, both in-clinic and at home

September is World #Alzheimers Month. We're honored to work with INmune Bio Inc. on a Ph1 POC study of XPro1595, a protein biologic with a novel MOA targeting pathological inflammation using #digitalbiomarkers in a real-world setting, both in-clinic and at home

🌟💬 Xtalks Spotlight: CJ Barnum from INmune Bio Inc., and Brian Murphy from Cumulus Neuroscience, delve into the significance of EEG biomarkers in #Alzheimer ’s research. They also share groundbreaking pilot study findings from Cumulus Neuroassessment Platform: buff.ly/4atFTlU

September is World #Alzheimers Month. We're honored to work with INmune Bio Inc. on a Ph1 POC study of XPro1595, a protein biologic with a novel MOA targeting pathological inflammation using #digitalbiomarkers in a real-world setting, both in-clinic and at home

1/3
On #WorldCancerResearchDay we’re acknowledging some of the fantastic sponsors we’ve worked with in early phase #oncology studies.

We were honoured to partner with INmune Bio Inc. for several of its studies, as well as University Hospital Southampton.

#Oncology #CancerResearch

I've participated in the Walk to End Alzheimer's 3 times, & will be walking this year. I was thrilled to learn that a research company called InMuneBio received $1 million seed money to look at treating Alzheimer's from an entirely different perspective.

Gives me a bit more

Came across co called inmunebio that’s developing treatments 4 various diseases but 1 called Xpro1595 is supposed 2 ⬇️ neuroinflammation & help w chronic immune dysregulation that causes it. Given these 2 things seem to play role in ME/CFS wonder if this 1 has potential for us?

Another episode of INside INmune Bio is out! 🎥 Our CFO and host David Moss unravels the 'master cytokine,' tumor necrosis factor, with our CEO Dr. RJ Tesi. Watch the full episode here: bit.ly/47V0Cho

September is World #Alzheimers Month. We're honored to work with INmune Bio Inc. on a Ph1 POC study of XPro1595, a protein biologic with a novel MOA targeting pathological inflammation using #digitalbiomarkers in a real-world setting, both in-clinic and at home

Dr. Malu Tansey Alzheimer's Association The National Institute on Aging (NIA) Columbia University INmune Bio Inc. CJ Barnum David Gate Brigham and Women's Hospital go Lynn van Olst!

@INmunebio CEO, Dr. RJ Tesi on Why Do So Many Alzheimer's Clinical Trials Fail? clinicalleader.com/doc/why-do-so-…